Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1
Recruiting · NCT07552922 · Interventional (participants receive a specific treatment) · Lead sponsor: St Vincent's Hospital, Sydney
View the official record on ClinicalTrials.gov →Interventions studied
Semi-structured Interview
What this trial is about
This study aims to explore the perceptions of men with prostate cancer (PCa) and high-risk biochemical recurrence (BCR) regarding the risk of breast-related side effects, including gynaecomastia, from treatment.
Who can take part
Age range
18 Years and older
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Men with high-risk BCR PCa but no ADT+/-ARPI experience.
- Men with ADT+/-ARPI experience who have experienced breast-related side effects from this treatment.
Exclusion criteria
- Men receiving psychiatric care as a consequence of their prostate cancer diagnosis or treatment thereof.
Where it is running
1 location listed.
- Kinghorn Cancer Centre - Sydney, New South Wales, Australia